Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

E1(115368), ALPHACVAC, Redoxis

Reference number
Coordinator Redoxis AB
Funding from Vinnova SEK 2 279 633
Project duration September 2021 - June 2025
Status Completed
Venture Eurostars

Important results from the project

The project did not achieve all of its set objective and expected results. The technology for inducing and then treating disease with viral vectors requires further development to become useful. The project has generated valuable knowledge and Redoxis has successfully established and validated a preclinical ALS model that is now a resource in the company´s offering to external actors in drug development.

Expected long term effects

In the longer term, the established ALS model, together with the in-depth knowledge of its use, is expected to help Redoxis attract new clients who wish to evaluate experimental treatment strategies in a relevant preclinical context. The application of the model thus has the potential to promote the development of new therapies, which in the long run can help reduce both patient suffering and the burden on the healthcare system.

Approach and implementation

The project planning, implementation and evaluation took place in close collaboration with the project partner. The partner was responsible for the development and production of virus vectors, which were then used in attempts to induce a disease model in mice at Redoxis. In parallel, an existing ALS model was established at Redoxis. The collaboration has worked well, but the evaluated technology did not prove to be efficient for inducing disease in the current model.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 4 July 2025

Reference number 2021-03355